Cylene Pharmaceuticals Inc., 5820 Nancy Ridge Drive, Suite 200, San Diego, CA 92121, USA.
Bioorg Med Chem Lett. 2012 Jan 1;22(1):45-8. doi: 10.1016/j.bmcl.2011.11.087. Epub 2011 Nov 30.
Protein kinase CK2 is a potential drug target for many diseases including cancer and inflammation disorders. The crystal structure of clinical candidate CX-4945 1 with CK2 revealed an indirect interaction with the protein through hydrogen bonding between the NH of the 3-chlorophenyl amine and a water molecule. Herein, we investigate the relevance of this hydrogen bond by preparing several novel tricyclic derivatives lacking a NH moiety at the same position. This SAR study allowed the discovery of highly potent CK2 inhibitors.
蛋白激酶 CK2 是许多疾病(包括癌症和炎症性疾病)的潜在药物靶点。临床候选药物 CX-4945 1 与 CK2 的晶体结构显示,通过 3-氯苯甲胺的 NH 与水分子之间的氢键,与蛋白质发生间接相互作用。在此,我们通过制备几个在相同位置缺乏 NH 部分的新型三环衍生物来研究该氢键的相关性。这项 SAR 研究发现了具有高 CK2 抑制活性的化合物。